Altimmune Inc Sustainability Reports

Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for obesity and liver diseases. Its primary product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist in development for obesity and metabolic dysfunction-associated steatohepatitis (MASH).

Sector: Manufacturing

Country: United States

Exchange: Nasdaq

LEI: 549300EOYCQ8SW3NVE64

FIGI: BBG001SNS461

5 reports from 2018 to 2023

• Altimmune Inc 2023 Annual Report on Form 10-K
• Altimmune Inc 2022 Annual Report on Form 10-K
• Altimmune Inc 2021 Annual Report on Form 10-K
• Altimmune Inc 2020 Annual Report on Form 10-K
• Altimmune Inc 2018 Annual Report on Form 10-K